AlumisALMS
NASDAQPharmaceuticals
No cached AI snapshot yet for ALMS.
Be the first to run a multi-agent analysis on this ticker.
Key Stats
224 employees127.20M shares outstandinglisted 2024-06-28
Next earnings ~May 5, 2026
About Alumis
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.
Latest News
Showing market-wide stock news
Bitcoin retreats after crypto bill setback, Fed next
This BlackRock strategist opposes a Fed hike. Here are the funds she recommends.
Gold outlook hinges on Fed signals; metal could test $4,200: Kotak Sec
US Dollar: Higher yields and oil support – MUFG
Bond Investors Are on Edge. Here's Why Stock Investors Should Pay Attention.
Wall St futures edge higher in countdown to Fed decision
Related Stocksin Pharmaceuticals
Ready to see the live AI view on ALMS?
Launch a real-time multi-agent room — Claude, GPT, Gemini, DeepSeek, Grok, and Qwen analyzing ALMS side-by-side with live signals.